echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > EU approves bispecific antibody Tecvayli (teclistamab) for the treatment of adults with relapsed/refractory multiple myeloma (RRMM)

    EU approves bispecific antibody Tecvayli (teclistamab) for the treatment of adults with relapsed/refractory multiple myeloma (RRMM)

    • Last Update: 2022-09-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Janssen announced today that the European Commission (EC) has approved the conditional marketing of Tecvayli (teclistamab), a bispecific antibody targeting B cell maturation antigen (BCMA), for the treatment of adults with relapsed/refractory multiple myeloma (RRMM).


    This approval of teclistamab is based on results from the Phase 1/2 MajesTEC-1 trials (NCT03145181 and NCT04557098) in which patients with relapsed/refractory disease received teclistamab at 1.


     

     

     

    Multiple myeloma is the second most common hematological malignancy, accounting for about 10% of hematological malignancies


    BCMA is a popular target for the treatment of B-cell blood cancers


    References:

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.